$BCTX

BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025

PHILADELPHIA and VANCOUVER, British Columbia, Nov. 18, 2025 ( GLOBE NEWSWIRE ) -- BriaCell Therapeutics Corp. ( Nasdaq: BCTX, BCTXW ) ( TSX: BCT ) ( "BriaCell" or the "Company" ) , a clinical-stage biotechnology company that develops novel immunotherapies to transform cancer care, is pleased to ...

Original reporting
GlobeNewswire · BriaCell Therapeutics Corp.
Published Nov 18, 2025, 12:30 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Nov 18, 2025, 2:33 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
BriaCell Selected to Present Phase 2 & 3 Clinical Data at SABCS® 2025 — source image
Decision brief

The 30-second read

$BCTXBullishMed
01

Why it matters

Positive clinical data can enhance investor confidence, potentially leading to stock appreciation. Conversely, any negative or inconclusive results could result in stock decline.

02

Market read

The event is highly relevant for biotech investors, especially those focused on oncology and immunotherapy sectors.

03

What to watch

Potential delays in data release or regulatory hurdles could negatively impact stock performance.

Timing: Upcoming event in November 2025

Background

BriaCell is a clinical-stage biotech focusing on immunotherapies for cancer. The upcoming presentation at SABCS 2025 is a key milestone for validating its clinical progress.

Company-level read

Ticker impact

$BCTXBullishHigh confidence
Context

Biotech sector, specifically cancer immunotherapies

Expected impact

Moderate upward movement in BCTX stock price over the next 1-3 months.

Evidence & confidence

The presentation of clinical data at a major conference often leads to increased visibility and validation of the company's technology, which can positively influence stock performance.

Market effects

Potential positive impact on biotech and immunotherapy sectors

Limited regional impact, primarily affecting North American biotech stocks

Moderate, as the event may attract international investor attention

Counterpoint

The clinical data presentation may not lead to a significant stock movement if results are not as positive as anticipated.

Key entities

  • BriaCell Therapeutics Corp.

    Developer of immunotherapies for cancer treatment.

  • SABCS 2025

    San Antonio Breast Cancer Symposium, a major conference for oncology research.

Related articles

$BCTXMedAI 9/10

BriaCell Presents Positive Clinical Data at ASCO 2026

BriaCell Therapeutics reported positive ASCO 2026 data for Bria-IMT in heavily pretreated metastatic breast cancer. Phase 2 results cited by the company showed 55% survival beyond 1 year and 27% beyond 2 years with the Phase 3-selected regimen; TWiST and quality-of-life analyses from the ongoing Phase 3 Bria-ABC study indicated meaningful benefit with no unexpected safety signals.

$BCTXHighAI 9/10

BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer

BriaCell Therapeutics (Nasdaq: BCTX; TSX: BCT) said its independent Data Safety Monitoring Board reviewed safety data from its pivotal Phase 3 Bria-ABC trial of Bria-IMT plus an immune checkpoint inhibitor in metastatic breast cancer and raised no safety concerns, recommending continuation without modifications. The DSMB issued its sixth consecutive positive recommendation; the study is under FDA Fast Track.

$RKLBMedAI 8/10

Rocket Lab Just Unveiled a Game-Changing Technology Worth Watching

Rocket Lab (RKLB) said it won a $397 million U.S. Space Force contract to develop, launch, and operate multiple Flatellites for the SB-AMTI program. Flatellites are slimmer, stackable satellites intended to increase deployments per launch and integrate with Rocket Lab’s Neutron rocket. The article cites analyst forecasts for revenue rising from $602M (2025) to $1.7B (2028).

$AVAVMedAI 8/10

Bloomberg: US to purchase anti-drone lasers for $400 million

Bloomberg reports the Pentagon will buy laser-based counter-drone systems from AeroVironment Inc. in a deal valued at at least $400 million. The contract is expected to supply the Army with dozens of Locust systems, described as an AI-enabled laser system for tracking and disabling small and medium UAVs. AeroVironment shares rose 8.1% intraday, according to the report.